Skip to content
OpenCapital
Get started

Xilio Therapeutics, Inc. XLO Q4 2024 Annual earnings

Reported March 11, 2025 · Before market open

Revenue$1.7MMiss by $21.5MDiluted EPS-$0.20Beat by $2.83
Revenue estimate$23.2M
EPS estimate-$3.03

Next report

Aug 13, 2026 (in a month)
Revenue estimate$12.7M
EPS estimate-$0.59

Versus estimates

Revenue

Q1 2026$12.7MBeat by $4.1MQ4 2025$13.7MBeat by $2.8MQ3 2025$19.1MBeat by $431.0KQ2 2025$8.1MMiss by $10.6MQ1 2025$2.9MMiss by $20.3M
Q4 2024$1.7MMiss by $21.5M

Diluted EPS

Q1 2026-$0.58Beat by $0.08Q4 2025-$0.85Beat by $0.83Q3 2025-$0.03Beat by $0.42Q2 2025-$0.16Beat by $0.94Q1 2025-$0.18Beat by $2.52
Q4 2024-$0.20Beat by $2.83

Ask the moment Xilio Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Xilio Therapeutics, Inc. report Q4 2024 earnings?
Xilio Therapeutics, Inc. (XLO) reported Q4 2024 earnings on March 11, 2025 before market open.
What were Xilio Therapeutics, Inc.'s Q4 2024 revenue and EPS?
Xilio Therapeutics, Inc. reported revenue of $1.7M and diluted EPS of $-0.20 for Q4 2024.
Did Xilio Therapeutics, Inc. beat estimates in Q4 2024?
Revenue missed the consensus estimate of $23.2M by $21.5M. EPS beat the consensus estimate of $-3.03 by $2.83.
Where can I find Xilio Therapeutics, Inc.'s Q4 2024 SEC filings?
You can read the 10-K periodic report (0001558370-25-002640) directly on SEC EDGAR. The filing index links above go to sec.gov.